AML (ACUTE MYELOGENOUS LEUKEMIA)
Clinical trials for AML (ACUTE MYELOGENOUS LEUKEMIA) explained in plain language.
Never miss a new study
Get alerted when new AML (ACUTE MYELOGENOUS LEUKEMIA) trials appear
Sign up with your email to follow new studies for AML (ACUTE MYELOGENOUS LEUKEMIA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to keep leukemia away after remission
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding venetoclax to standard chemotherapy (cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. About 232 participants who are already in remission will receive either the combination or chemo alone. The main goal is to…
Matched conditions: AML (ACUTE MYELOGENOUS LEUKEMIA)
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Fitness check may guide better leukemia care for seniors
Knowledge-focused OngoingThis study looks back at medical records of 725 older adults (over 65) with acute myeloid leukemia (AML). Researchers want to see if using a special 'fitness' score to choose treatment leads to longer survival. No new treatments are given; the goal is to learn which treatment app…
Matched conditions: AML (ACUTE MYELOGENOUS LEUKEMIA)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
CAR-T therapy patients monitored for years in new safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…
Matched conditions: AML (ACUTE MYELOGENOUS LEUKEMIA)
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC